EA026456B1 - Фармацевтическая композиция на основе антагониста crth2 и ингибитора протонного насоса для лечения эозинофильного эзофагита - Google Patents
Фармацевтическая композиция на основе антагониста crth2 и ингибитора протонного насоса для лечения эозинофильного эзофагита Download PDFInfo
- Publication number
- EA026456B1 EA026456B1 EA201491008A EA201491008A EA026456B1 EA 026456 B1 EA026456 B1 EA 026456B1 EA 201491008 A EA201491008 A EA 201491008A EA 201491008 A EA201491008 A EA 201491008A EA 026456 B1 EA026456 B1 EA 026456B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- methyl
- fluoro
- acetic acid
- methylindol
- indol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161576640P | 2011-12-16 | 2011-12-16 | |
| PCT/GB2012/000904 WO2013088109A1 (en) | 2011-12-16 | 2012-12-14 | Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201491008A1 EA201491008A1 (ru) | 2015-02-27 |
| EA026456B1 true EA026456B1 (ru) | 2017-04-28 |
Family
ID=47470031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201491008A EA026456B1 (ru) | 2011-12-16 | 2012-12-14 | Фармацевтическая композиция на основе антагониста crth2 и ингибитора протонного насоса для лечения эозинофильного эзофагита |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20140328861A1 (https=) |
| EP (1) | EP2790696A1 (https=) |
| JP (1) | JP2015500326A (https=) |
| KR (1) | KR20140113667A (https=) |
| CN (1) | CN104114169A (https=) |
| AU (1) | AU2012351342A1 (https=) |
| BR (1) | BR112014014558A8 (https=) |
| CA (1) | CA2859284A1 (https=) |
| EA (1) | EA026456B1 (https=) |
| IL (1) | IL233131A0 (https=) |
| MX (1) | MX2014007239A (https=) |
| SG (1) | SG11201402796SA (https=) |
| UA (1) | UA112667C2 (https=) |
| WO (1) | WO2013088109A1 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| GB201103837D0 (en) | 2011-03-07 | 2011-04-20 | Oxagen Ltd | Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid |
| GB201121557D0 (en) | 2011-12-15 | 2012-01-25 | Oxagen Ltd | Process |
| US9574004B2 (en) | 2012-08-21 | 2017-02-21 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an IL-4R antagonist |
| PT3889181T (pt) | 2012-09-07 | 2024-05-29 | Regeneron Pharma | Um anticorpo antagonista de il-4r para utilização no tratamento da dermatite atópica por administração |
| TWI633891B (zh) | 2013-06-04 | 2018-09-01 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法 |
| CN111437387B (zh) | 2013-06-21 | 2024-10-01 | 赛诺菲生物技术公司 | 通过施用il-4r拮抗剂治疗鼻息肉症的方法 |
| TWI682781B (zh) | 2013-07-11 | 2020-01-21 | 美商再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| WO2015034678A2 (en) | 2013-09-06 | 2015-03-12 | Aptalis Pharmatech, Inc. | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis |
| WO2015130975A1 (en) | 2014-02-28 | 2015-09-03 | Regeneron Pharmaceuticals, Inc. | Methods for treating skin infection by administering an il-4r antagonist |
| GB201407807D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
| GB201407820D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
| AU2015346150B2 (en) | 2014-11-14 | 2021-08-19 | Regeneron Pharmaceuticals, Inc. | Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist |
| JP6770522B2 (ja) | 2015-02-13 | 2020-10-14 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 全身性エリテマトーデスを予防し、及び／又は、治療するためのｐｔｇｄｒ−１及び／又はｐｔｇｄｒ−２アンタゴニスト |
| WO2017123401A1 (en) * | 2016-01-13 | 2017-07-20 | Children's Hospital Medical Center | Compositions and methods for treating allergic inflammatory conditions |
| RU2756270C2 (ru) * | 2016-07-21 | 2021-09-29 | Чиа Тай Тянцин Фармасьютикал Груп Ко., Лтд. | Производное индола, используемое в качестве ингибитора CRTH2 |
| TWI728172B (zh) * | 2016-08-18 | 2021-05-21 | 美商愛戴爾製藥股份有限公司 | 治療嗜伊紅性食道炎之方法 |
| HUE067888T2 (hu) | 2016-09-01 | 2024-11-28 | Regeneron Pharma | Módszerek az allergia megelõzésére vagy kezelésére egy IL-4R antagonista adagolásával |
| WO2018057776A1 (en) | 2016-09-22 | 2018-03-29 | Regeneron Pharmaceuticals, Inc. | Methods for treating severe atopic dermatitis by administering an il-4r inhibitor |
| US11053309B2 (en) | 2017-08-04 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating active eosinophilic esophagitis |
| CA3079946A1 (en) | 2017-10-30 | 2019-05-09 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4r antagonist |
| CN107987066B (zh) * | 2017-11-30 | 2020-06-26 | 正大天晴药业集团股份有限公司 | 作为crth2抑制剂的吲哚衍生物 |
| CN107936004B (zh) * | 2017-11-30 | 2020-05-05 | 正大天晴药业集团股份有限公司 | 作为crth2抑制剂的吲哚类衍生物 |
| CN107987072B (zh) * | 2017-11-30 | 2020-06-26 | 正大天晴药业集团股份有限公司 | 作为crth2抑制剂的吲哚类化合物 |
| CN107954995B (zh) * | 2017-11-30 | 2020-05-05 | 正大天晴药业集团股份有限公司 | 具有crth2抑制剂活性的吲哚衍生物 |
| US11859250B1 (en) | 2018-02-23 | 2024-01-02 | Children's Hospital Medical Center | Methods for treating eosinophilic esophagitis |
| EP3781588B1 (en) | 2018-04-20 | 2024-10-30 | Children's Hospital Medical Center | Blood biomarker for eosinophilic gastrointestinal disorders |
| US11292847B2 (en) | 2018-05-13 | 2022-04-05 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an IL-4R inhibitor |
| US12297501B2 (en) | 2019-02-25 | 2025-05-13 | Children's Hospital Medical Center | Methods for diagnosing and treating eosinophilic gastritis |
| CA3132587A1 (en) | 2019-03-21 | 2020-09-24 | Regeneron Pharmaceuticals, Inc. | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
| BR112022000740A2 (pt) | 2019-07-16 | 2022-07-05 | Sanofi Biotechnology | Métodos para tratamento ou prevenção de asma por administração de um antagonista de il-4r |
| WO2021026205A1 (en) | 2019-08-05 | 2021-02-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r antagonist |
| US11504426B2 (en) | 2019-08-05 | 2022-11-22 | Regeneron Pharmaceuticals, Inc. | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist |
| WO2022020464A1 (en) * | 2020-07-21 | 2022-01-27 | Ellodi Pharmaceuticals, L.P. | Modified release rapidly disintegrating compositions of proton pump inhibitors |
| EP4595953A1 (en) * | 2024-01-30 | 2025-08-06 | Dr. Falk Pharma Gmbh | Orally applicable suspension for the treatment of eosinophilic esophagitis in children |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010039982A1 (en) * | 2008-10-01 | 2010-04-08 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
| WO2010042652A2 (en) * | 2008-10-08 | 2010-04-15 | Amira Pharmaceuticals, Inc. | Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors |
| US20110124683A1 (en) * | 2007-11-13 | 2011-05-26 | Oxagen Limited | Use of CRTH2 Antagonist Compounds |
Family Cites Families (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE416649B (sv) | 1974-05-16 | 1981-01-26 | Haessle Ab | Forfarande for framstellning av foreningar som paverkar magsyrasekretionen |
| IL75400A (en) | 1984-06-16 | 1988-10-31 | Byk Gulden Lomberg Chem Fab | Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same |
| JPS6150978A (ja) | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
| GB2189699A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
| FI90544C (fi) | 1986-11-13 | 1994-02-25 | Eisai Co Ltd | Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi |
| JPH0768125B2 (ja) | 1988-05-18 | 1995-07-26 | エーザイ株式会社 | 酸不安定化合物の内服用製剤 |
| SE9301830D0 (sv) | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
| TWI275587B (en) | 1999-06-17 | 2007-03-11 | Takeda Chemical Industries Ltd | A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole |
| SE0200356D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| SE0200411D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| WO2003097042A1 (en) | 2002-05-16 | 2003-11-27 | Shionogi & Co., Ltd. | Pgd2 receptor antagonist |
| AU2003231509A1 (en) | 2002-05-16 | 2003-12-02 | Shionogi And Co., Ltd. | Compound exhibiting pgd 2 receptor antagonism |
| TW200307542A (en) | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
| SE0201635D0 (sv) | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
| SE0202241D0 (sv) | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
| WO2004032848A2 (en) | 2002-10-04 | 2004-04-22 | Millennium Pharmaceuticals, Inc. | Pgd2 receptor antagonists for the treatment of inflammatory diseases |
| MXPA05003660A (es) | 2002-10-21 | 2005-06-08 | Warner Lambert Co | Derivados de quinolina como antagonistas de crth2. |
| PL377314A1 (pl) | 2002-12-20 | 2006-01-23 | Amgen Inc. | Modulatory astmy i zapaleń na tle alergicznym |
| SE0301009D0 (sv) | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
| SE0301010D0 (sv) | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
| PT1471057E (pt) | 2003-04-25 | 2006-05-31 | Actimis Pharmaceuticals Inc | Derivados de acido pirimidinilacetico uteis para o tratamento de doencas mediadas por crth2 |
| SE0301569D0 (sv) | 2003-05-27 | 2003-05-27 | Astrazeneca Ab | Novel compounds |
| US20050038070A1 (en) | 2003-07-09 | 2005-02-17 | Amgen Inc. | Asthma and allergic inflammation modulators |
| SE0302232D0 (sv) | 2003-08-18 | 2003-08-18 | Astrazeneca Ab | Novel Compounds |
| SA04250253B1 (ar) | 2003-08-21 | 2009-11-10 | استرازينيكا ايه بي | احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن |
| US20070232681A1 (en) | 2003-10-14 | 2007-10-04 | Oxagen Limited | Compounds Having Crth2 Antagonist Activity |
| WO2005040112A1 (en) | 2003-10-14 | 2005-05-06 | Oxagen Limited | Compounds with pgd2 antagonist activity |
| GB0324763D0 (en) | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
| SE0303180D0 (sv) | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
| CN100584844C (zh) | 2004-01-31 | 2010-01-27 | 艾克提麦斯医药品有限公司 | 咪唑[1,2-c]嘧啶基乙酸衍生物 |
| JP4861976B2 (ja) | 2004-03-11 | 2012-01-25 | アクテリオン ファーマシューティカルズ リミテッド | インドール−１−イル酢酸誘導体 |
| US7714132B2 (en) | 2004-03-11 | 2010-05-11 | Actelion Pharmaceuticals, Ltd. | Tetrahydropyridoindole derivatives |
| CA2561564A1 (en) | 2004-04-07 | 2005-10-27 | Millennium Pharmaceuticals, Inc. | Pgd2 receptor antagonists for the treatment of inflammatory diseases |
| US20050234030A1 (en) | 2004-04-20 | 2005-10-20 | Wilmin Bartolini | Modulators of CRTH2, COX-2 and FAAH |
| GB0409921D0 (en) | 2004-05-04 | 2004-06-09 | Novartis Ag | Organic compounds |
| EP1758874A1 (en) | 2004-05-29 | 2007-03-07 | 7TM Pharma A/S | Substituted thiazoleacetic acids as crth2 ligands |
| EP1758579A1 (en) | 2004-05-29 | 2007-03-07 | 7TM Pharma A/S | Crth2 receptor ligands for medicinal uses |
| US20090105218A1 (en) | 2004-05-29 | 2009-04-23 | 7Tm Pharma A/S | CRTH2 Receptor Ligands For Therapeutic Use |
| MY144903A (en) | 2004-06-17 | 2011-11-30 | Novartis Ag | Pyrrolopyridine derivatives and their use as crth2 antagonists |
| GB0415320D0 (en) | 2004-07-08 | 2004-08-11 | Astrazeneca Ab | Novel compounds |
| GB0418830D0 (en) | 2004-08-24 | 2004-09-22 | Astrazeneca Ab | Novel compounds |
| WO2006034419A2 (en) | 2004-09-21 | 2006-03-30 | Athersys, Inc. | Indole acetic acids exhibiting crth2 receptor antagonism and uses thereof |
| GB0422057D0 (en) | 2004-10-05 | 2004-11-03 | Astrazeneca Ab | Novel compounds |
| UY29223A1 (es) | 2004-11-23 | 2006-06-30 | Astrazeneca Ab | Ácidos fenoxiacéticos sustituidos, composiciones farmacéuticas que los contienen y procesos para su preparación |
| GB0427381D0 (en) | 2004-12-14 | 2005-01-19 | Novartis Ag | Organic compounds |
| GB0500604D0 (en) | 2005-01-13 | 2005-02-16 | Astrazeneca Ab | Novel process |
| WO2006091674A1 (en) | 2005-02-24 | 2006-08-31 | Millennium Pharmaceuticals, Inc. | Pgd2 receptor antagonists for the treatment of inflammatory diseases |
| GB0505048D0 (en) | 2005-03-11 | 2005-04-20 | Oxagen Ltd | Compounds with PGD antagonist activity |
| ZA200709817B (en) | 2005-04-21 | 2009-02-25 | Serono Lab | 2,3 substituted pyrazine sulfonmides as inhibitors of CRTH2 |
| GB0510585D0 (en) | 2005-05-24 | 2005-06-29 | Novartis Ag | Organic compounds |
| PL1891075T3 (pl) | 2005-05-24 | 2011-12-30 | Merck Serono Sa | Spiropochodne tricykliczne jako modulatory CRTH2 |
| GB0510584D0 (en) | 2005-05-24 | 2005-06-29 | Novartis Ag | Organic compounds |
| GB0512944D0 (en) | 2005-06-24 | 2005-08-03 | Argenta Discovery Ltd | Indolizine compounds |
| DE602005013372D1 (de) * | 2005-07-29 | 2009-04-30 | Rottapharm Spa | Kombination aus Itriglumid und PPI zur Behandlung von gastrointestinalen- und assozierten Krankheiten |
| US7696222B2 (en) | 2005-08-12 | 2010-04-13 | Merck Frosst Canada Ltd | Indole derivatives as CRTH2 receptor antagonists |
| US20070203209A1 (en) | 2005-08-18 | 2007-08-30 | Wilmin Bartolini | Useful indole compounds |
| GB0518494D0 (en) | 2005-09-09 | 2005-10-19 | Argenta Discovery Ltd | Thiazole compounds |
| GB0518783D0 (en) | 2005-09-14 | 2005-10-26 | Argenta Discovery Ltd | Indolizine compounds |
| DK1928457T3 (da) | 2005-09-30 | 2013-02-04 | Pulmagen Therapeutics Asthma Ltd | Quinoliner og deres terapeutiske anvendelse |
| EP1937632A1 (en) | 2005-10-06 | 2008-07-02 | Astra Zeneca AB | Novel compounds |
| TW200745003A (en) | 2005-10-06 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| GB0521275D0 (en) | 2005-10-19 | 2005-11-30 | Argenta Discovery Ltd | 3-Aminoindole compounds |
| EP1948630A2 (en) | 2005-11-05 | 2008-07-30 | AstraZeneca AB | Novel compounds |
| WO2007062678A1 (en) | 2005-11-29 | 2007-06-07 | 7Tm Pharma A/S | Phenoxyacetic acid derivatives as crth2 receptor ligands |
| GB0524427D0 (en) | 2005-11-30 | 2006-01-11 | 7Tm Pharma As | Use of receptor ligands in threapy |
| GB0524428D0 (en) | 2005-11-30 | 2006-01-11 | 7Tm Pharma As | Medicinal use of receptor ligands |
| WO2007062677A1 (en) | 2005-11-30 | 2007-06-07 | 7Tm Pharma A/S | Thiazolyl- and pyrimidinyl-acetic acids and their use as crth2 receptor ligands |
| TW200732296A (en) | 2005-12-15 | 2007-09-01 | Astrazeneca Ab | Novel compounds |
| JP2009538289A (ja) | 2006-05-26 | 2009-11-05 | アストラゼネカ・アクチエボラーグ | ビアリールまたはヘテロアリール置換インドール |
| GB0611781D0 (en) | 2006-06-14 | 2006-07-26 | Argenta Discovery Ltd | 2-Oxo-2H-Chromene Compounds |
| CA2658496A1 (en) | 2006-07-22 | 2008-01-31 | Oxagen Limited | 2-{5-fluoro-2-methyl-3-[2-(phenylsulfonyl)benzyl]-1h-indol-yl} acetic acid derivatives and esters thereof having crth2 antagonist activity |
| AU2007286829B2 (en) | 2006-08-21 | 2013-05-02 | Array Biopharma, Inc. | 4-substituted phenoxyphenylacetic acid derivatives |
| AU2006352195A1 (en) | 2006-12-21 | 2008-06-26 | Argenta Discovery Limited | CRTH2 antagonists |
| GB0625842D0 (en) | 2006-12-22 | 2007-02-07 | Argenta Discovery Ltd | Indolizine derivatives |
| EP2136804A1 (en) | 2007-03-21 | 2009-12-30 | Argenta Oral Therapeutics Limited | Indolizine acetic acid derivatives as crth2 antagonists |
| AU2007350688B2 (en) | 2007-03-29 | 2011-02-24 | Pulmagen Therapeutics (Asthma) Limited | Quinoline derivatives as CRTH2 receptor ligands |
| EP2176240A1 (en) | 2007-06-21 | 2010-04-21 | Actimis Pharmaceuticals, Inc., | Amine salts of a crth2 antagonist |
| GB0722216D0 (en) * | 2007-11-13 | 2007-12-27 | Oxagen Ltd | Use of crth2 antagonist compounds |
| DK2229358T3 (da) * | 2007-12-14 | 2011-07-04 | Pulmagen Therapeutics Asthma Ltd | Indoler og deres terapeutiske anvendelse |
| ES2471919T3 (es) | 2007-12-19 | 2014-06-27 | Amgen, Inc | Derivados de ácido fenilac�tico como moduladores de inflamación |
| US7750027B2 (en) | 2008-01-18 | 2010-07-06 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
| CA2712017C (en) * | 2008-01-18 | 2016-08-09 | Oxagen Limited | Compounds having crth2 antagonist activity |
| JP2011509991A (ja) | 2008-01-22 | 2011-03-31 | オキサジェン リミテッド | Ｃｒｔｈ２アンタゴニスト活性を有する化合物 |
| EP2265581A1 (en) | 2008-01-22 | 2010-12-29 | Oxagen Limited | Compounds having crth2 antagonist activity |
| WO2010008864A2 (en) * | 2008-06-24 | 2010-01-21 | Amira Pharmaceuticals, Inc. | Cycloalkane[b]indole angtagonists of prostaglandin d2 receptors |
| JP2012072061A (ja) * | 2009-01-29 | 2012-04-12 | Eisai R & D Management Co Ltd | 新規組成物 |
| JP2012533633A (ja) * | 2009-07-20 | 2012-12-27 | ベテゲン・エルエルシー | 経口投与のための安定な薬学的オメプラゾール製剤 |
| US8815917B2 (en) | 2009-08-05 | 2014-08-26 | Panmira Pharmaceuticals, Llc | DP2 antagonist and uses thereof |
| US20120148581A1 (en) * | 2009-08-17 | 2012-06-14 | The Regents Of The University Of California | Use of nkg2d inhibitors for treating cardiovascular and metabolic diseases, such as type 2 diabetes |
| EP2521713A4 (en) | 2010-01-06 | 2013-10-02 | Panmira Pharmaceuticals Llc | ANTAGONIST OF DP2 AND ITS USES |
-
2012
- 2012-12-14 SG SG11201402796SA patent/SG11201402796SA/en unknown
- 2012-12-14 MX MX2014007239A patent/MX2014007239A/es unknown
- 2012-12-14 JP JP2014546622A patent/JP2015500326A/ja active Pending
- 2012-12-14 AU AU2012351342A patent/AU2012351342A1/en not_active Abandoned
- 2012-12-14 UA UAA201407393A patent/UA112667C2/uk unknown
- 2012-12-14 KR KR1020147018762A patent/KR20140113667A/ko not_active Withdrawn
- 2012-12-14 EA EA201491008A patent/EA026456B1/ru unknown
- 2012-12-14 US US14/365,306 patent/US20140328861A1/en not_active Abandoned
- 2012-12-14 CN CN201280066423.2A patent/CN104114169A/zh active Pending
- 2012-12-14 CA CA2859284A patent/CA2859284A1/en not_active Abandoned
- 2012-12-14 WO PCT/GB2012/000904 patent/WO2013088109A1/en not_active Ceased
- 2012-12-14 EP EP12808859.8A patent/EP2790696A1/en not_active Withdrawn
- 2012-12-14 BR BR112014014558A patent/BR112014014558A8/pt not_active Application Discontinuation
-
2014
- 2014-06-15 IL IL233131A patent/IL233131A0/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110124683A1 (en) * | 2007-11-13 | 2011-05-26 | Oxagen Limited | Use of CRTH2 Antagonist Compounds |
| WO2010039982A1 (en) * | 2008-10-01 | 2010-04-08 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
| WO2010042652A2 (en) * | 2008-10-08 | 2010-04-15 | Amira Pharmaceuticals, Inc. | Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors |
Non-Patent Citations (3)
| Title |
|---|
| A. STRAUMANN, HOESLI S., BUSSMANN CH., STUCK M., PERKINS M., COLLINS L. P., PAYTON M., PETTIPHER R., HUNTER M., STEINER J., SIMON : "Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis", ALLERGY, MUNKSGAARD., vol. 68, no. 3, 1 March 2013 (2013-03-01), pages 375 - 385, XP055054697, ISSN: 01054538, DOI: 10.1111/all.12096 * |
| JAVIER MOLINA INFANTE; LUCIA FERRANDO LAMANA; CRISTINA RIPOLL; MOISES HERNANDEZ ALONSO; JOSE M. MATEOS; MIGUEL FERNANDEZ BERMEJO; : "Esophageal Eosinophilic Infiltration Responds to Proton Pump Inhibition in Most Adults", CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, AMERICAN GASTROENTEROLOGICAL ASSOCIATION,, US, vol. 9, no. 2, US, pages 110 - 117, XP028187339, ISSN: 1542-3565, DOI: 10.1016/j.cgh.2010.09.019 * |
| KATHRYN A. PETERSON ; KRISTEN L. THOMAS ; KRISTEN HILDEN ; LYSKA L. EMERSON ; JASON C. WILLS ; JOHN C. FANG: "Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis", DIGESTIVE DISEASES AND SCIENCES, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NE, vol. 55, no. 5, 18 June 2009 (2009-06-18), Ne, pages 1313 - 1319, XP019816553, ISSN: 1573-2568 * |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014014558A8 (pt) | 2017-07-04 |
| WO2013088109A1 (en) | 2013-06-20 |
| AU2012351342A1 (en) | 2014-07-24 |
| KR20140113667A (ko) | 2014-09-24 |
| CN104114169A (zh) | 2014-10-22 |
| BR112014014558A2 (pt) | 2017-06-13 |
| IL233131A0 (en) | 2014-07-31 |
| CA2859284A1 (en) | 2013-06-20 |
| US20140328861A1 (en) | 2014-11-06 |
| NZ626990A (en) | 2016-01-29 |
| MX2014007239A (es) | 2014-08-08 |
| JP2015500326A (ja) | 2015-01-05 |
| EP2790696A1 (en) | 2014-10-22 |
| SG11201402796SA (en) | 2014-06-27 |
| UA112667C2 (uk) | 2016-10-10 |
| EA201491008A1 (ru) | 2015-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA026456B1 (ru) | Фармацевтическая композиция на основе антагониста crth2 и ингибитора протонного насоса для лечения эозинофильного эзофагита | |
| TWI607754B (zh) | 醫藥組合 | |
| US20130052190A1 (en) | CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions | |
| WO2019067843A1 (en) | PYRAZOLO [3,4-B] PYRAZINE DERIVATIVES AS INHIBITORS OF PHOSPHATASE SHP2 | |
| KR20180006447A (ko) | Braf-v600-관련 질환의 치료에 사용하기 위한 plx-8394 또는 plx-7904 | |
| TWI873485B (zh) | 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案 | |
| US20110124683A1 (en) | Use of CRTH2 Antagonist Compounds | |
| AU2018234903B2 (en) | Combination therapies for the treatment of breast cancer | |
| CN101522187A (zh) | 用于治疗、减轻、改善或缓解后段眼病的组合物和方法 | |
| JP2000198734A (ja) | 胃運動性減弱および関連疾患の治療のための運動性増強薬 | |
| JP2005503382A (ja) | 偏頭痛の治療のために他の抗偏頭痛薬と組み合わせたｂｉｂｎ４０９６の使用 | |
| TW200904424A (en) | Pharmaceutical composition for remedy of lower urinary tract symptoms associated with benign prostate hyperplasia | |
| EP2914264B1 (en) | A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (hcc) | |
| US9511068B2 (en) | Composition for treating or preventing diseases caused by vascular permeability, containing imatinib or pharmaceutically acceptable salt thereof as active ingredient | |
| EP1713543B1 (fr) | Utilisation de derives d'indolizine 1,2,3 substitues pour le traitement de maladies liees a une angiogenese pathologique choroidienne | |
| JP2005047909A (ja) | ピペリジン誘導体を有効成分とする掻痒治療剤 | |
| CN114746093A (zh) | 治疗血管畸形的方法 | |
| EP3057571A1 (en) | Proton pump inhibitor paste compositions | |
| JP2022500351A (ja) | 疼痛使用のためのｃｈ２４ｈ阻害剤 | |
| JP7395358B2 (ja) | ｍＴＯＲ経路の調節異常に関連する疾患の治療 | |
| CN1466587A (zh) | 含有2-芳基-8-氧代二氢嘌呤衍生物作为活性成分的痴呆症治疗剂 | |
| HK40116611A (zh) | 用於治疗癌症的包含cdk2抑制剂和cdk4抑制剂的方法和给药方案 | |
| GB2524351A (en) | Proton Pump Inhibitor Paste Compositions |